ICC award looms in US-Chinese biotech dispute
A US biotech company and its Chinese partner are awaiting an ICC award in a US$200 million-plus dispute over a collaboration to develop cancer-fighting antibodies.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.